Mobile

An eight-week, double-blind, group sequential design, placebo controlled trial to evaluate the safety and efficacy of the co-administration of sertraline and elzasonan (CP-448,187) in outpatients with...

Update Il y a 5 ans
Reference: EUCTR2005-004780-34

An eight-week, double-blind, group sequential design, placebo controlled trial to evaluate the safety and efficacy of the co-administration of sertraline and elzasonan (CP-448,187) in outpatients with major depressive disorder

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

To compare the efficacy of the administration of sertraline and elzasonan combination (SEC) to sertraline monotherapy in the acute treatment of subjects with MDD as measured by Montgomery-Asberg Depression Rating Scale (MADRS) remission rates at Week 8.

Inclusion criteria

  • -Major Depressive Disorder (MDD)

Links